{"cdcTestId":"2021-0007","testcaseName":"Dose #1 and Dose #2 of a Non-U.S. Covid-19 Vaccine ","vaccineGroup":"COVID-19","evaluationTestType":"All Valid: Forecast Test","forecastTestType":"Recommended based on interval","assessmentDate":"2022-10-19T00:00:00","patient":{"dob":"2001-09-21T00:00:00","gender":"M"},"evaluation":{"seriesStatus":"Not complete","administeredDoses":[{"dateAdministered":"2022-09-21T00:00:00","vaccineName":"COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL ","cvx":"210","mvx":"","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-10-19T00:00:00","vaccineName":"COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL ","cvx":"210","mvx":"","evaluationStatus":"Valid","evaluationReason":null}]},"forecast":{"forecastNum":"3","earliestDate":"2022-12-14T00:00:00","recommendedDate":"2022-12-14T00:00:00","pastDueDate":"0001-01-01T00:00:00"},"doses":[{"dateAdministered":"2022-09-21T00:00:00","vaccineName":"COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL ","cvx":"210","mvx":"","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-10-19T00:00:00","vaccineName":"COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL ","cvx":"210","mvx":"","evaluationStatus":"Valid","evaluationReason":null}],"dateAdded":"2020-10-06T20:00:00","dateUpdated":"2022-09-27T09:38:29.888","generalDescription":"This test case describes when a patient is administered the first and second dose of a two-dose Non-US Covid-19 vaccine (e.g Astra Zeneca), but still a WHO Covid-19 vaccine, that the doses are considered to be valid.  Another dose should be forecast.","changedInVersion":"4.27","reasonForChange":"v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group. \nv4.20: Updated test case to align with Interim Clinical Considerations for \u0022People who received Covid-19 vaccine outside of the United States\u0022 by forecasting a third dose."}